

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



友芝友生物製藥

WUHAN YZY BIOPHARMA CO., LTD.

武漢友芝友生物製藥股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2496)

**INSIDE INFORMATION
COMPLETION OF THE H SHARE FULL CIRCULATION**

This announcement is made by Wuhan YZY Biopharma Co., Ltd. (the “**Company**”) under Rule 13.09(2)(a) of the Rules Governing the Listing of Securities (the “**Listing Rules**”) on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

References are made to the announcements of the Company dated May 12, 2025, January 26, 2026 and February 4, 2026 (the “**Announcements**”) in relation to the H Share Full Circulation. Unless otherwise defined, capitalised terms used herein have the same meanings as those defined in the Announcements.

COMPLETION OF THE H SHARE FULL CIRCULATION

The Board is pleased to announce that, the conversion of an aggregate of 68,010,299 Unlisted Shares into H Shares was completed on March 30, 2026 and the listing of the Converted H Shares on the Stock Exchange will commence at 9:00 a.m. on March 31, 2026.

SHAREHOLDING STRUCTURE

The shareholding structure of the Company immediately before and upon completion of the Conversion and Listing is set out below:

Type of Shares	Immediately before completion of the Conversion and Listing		Immediately upon completion of the Conversion and Listing	
	Number of Shares (shares)	Approximate percentage ^(Note) (%)	Number of Shares (shares)	Approximate percentage ^(Note) (%)
Unlisted Domestic Shares	75,510,642	38.95	14,370,087	7.41
Unlisted Foreign Shares	6,869,744	3.54	—	—
H Shares	<u>111,468,814</u>	<u>57.50</u>	<u>179,479,113</u>	<u>92.59</u>
Total	<u>193,849,200</u>	<u>100</u>	<u>193,849,200</u>	<u>100</u>

Note: The percentages have been rounded up to the nearest two decimal places and any differences between the totals and sums of amounts listed in the table are due to rounding.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares and other securities of the Company.

By order of the Board
Wuhan YZY Biopharma Co., Ltd.
Dr. Zhou Pengfei
*Chairman of the Board, Executive Director
and Chief Executive Officer*

Wuhan, PRC, March 30, 2026

As at the date of this announcement, the Board comprises Dr. Zhou Pengfei and Mr. Wen Zhicheng as executive directors; Dr. Yuan Qian, Dr. Zhou Hongfeng, Mr. Pang Zhenhai, Dr. Hui Xiwu and Mr. Xie Shouwu as non-executive directors; and Dr. Cheng Bin, Ms. Fu Lili, Dr. Deng Yuezhen and Dr. Chen Bin as independent non-executive directors.